Skip to main content

Nuvectis Pharma Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

NVCT$21.08+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (included on signature page). *

POWER OF ATTORNEY

We, the undersigned directors and/or executive officers of Nuvectis Pharma, Inc., hereby severally constitute and appoint Ron Bentsur, acting singly, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her in any and all capacities, to sign this report and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or appropriate to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

​​​​​
SignatureTitleDate
​​​​​
/s/ Ron Bentsur​Chairman, Chief Executive Officer and President​​
Ron Bentsur​(Principal Executive Officer)​February 25, 2025
​​​​​
/s/ Michael J Carson​Vice President of Finance​​
Michael J Carson​(Principal Financial and Accounting Officer)​February 25, 2025
​​​​​
/s/ Kenneth Hoberman​​​​
Kenneth Hoberman​Director​February 25, 2025
​​​​​
/s/ James F. Olivero III​​​​
James F. Oliviero III​Director​February 25, 2025
​​​​​
/s/ Matthew L. Kaplan​​​​
Matthew L. Kaplan​Director​February 25, 2025
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.